Invasive Bladder Urothelial Carcinoma — Trials

Invasive Bladder Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

45 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 26
Recruiting: 15
Ph III recruiting: 2
Growth YoY: —
Industry share: 4%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (8)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04164082	Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer	active not recruiting	Phase 2	161	National Cancer Institute (NCI)NIH	3	Aug 11, 2026	clinicaltrials
NCT03744793	Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer	active not recruiting	Phase 2	18	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026